newscientist.com article, page-32

You will be hard pressed to find any Biotech that has completed Phase II successfully with a market cap under $100m. $100m seems to be the bottom benchmark and that seemed to be for Orphan Drugs with a market of limited Customers, circa 50,000 customers Globally. With 7 million potential Customers and growing LCT has some serious upside, coupled with the possible application to Huntingtons and Alzheimers, plus the possible licensing of NTCell to other research houses and stem cell clinics. It is still the only delivery system in the world that you don't have to lower the patients immunity levels .